Related Experiment Video

Updated: Aug 19, 2026

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

Ophthalmic timolol treatment causing altered hypoglycemic response in a diabetic patient

T M Velde, F E Kaiser

    Archives of Internal Medicine
    |August 1, 1983
    PubMed

    Insights

    Topical timolol maleate altered diabetic hypoglycemia symptoms, causing altered mental status and glucose resistance. Caution is advised when using beta-blockers in diabetic patients prone to hypoglycemia.

    Area of Science:

    • Ophthalmology
    • Endocrinology
    • Pharmacology

    Background:

    • Diabetic patients are prone to hypoglycemia.
    • Ophthalmic timolol maleate is a beta-adrenergic blocker used to treat glaucoma.
    • Hypoglycemia symptoms typically include sweating, uneasiness, and resolve with glucose.

    Observation:

    • A diabetic patient on ophthalmic timolol maleate experienced altered hypoglycemic symptoms.
    • During timolol therapy, hypoglycemia presented with changed mental status, including seizures.
    • The patient showed relative resistance to glucose treatment during these episodes.

    Findings:

    • Topical beta-adrenergic blockers, like timolol maleate, can mask or alter typical hypoglycemic symptoms in diabetic patients.
    • Altered mental status and resistance to glucose treatment are potential signs of hypoglycemia during timolol therapy.
    • The cardiovascular and metabolic effects of beta-blockers may interfere with the body's response to low blood sugar.

    Implications:

    • Clinicians should exercise caution when prescribing ophthalmic beta-adrenergic blockers to diabetic patients.
    • Diabetic patients on timolol maleate should be monitored closely for atypical hypoglycemia symptoms.
    • Increased awareness and monitoring are crucial for managing hypoglycemia in diabetic patients using topical beta-blockers.

    More Related Videos

    A Reversible Silicon Oil-Induced Ocular Hypertension Model in Mice09:03

    A Reversible Silicon Oil-Induced Ocular Hypertension Model in Mice

    Published on: November 15, 2019

    Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents10:10

    Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

    Published on: February 15, 2022

    Related Concept Videos

    Open Angle Glaucoma: Treatment01:27

    Open Angle Glaucoma: Treatment

    In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
    Drugs such as carbonic anhydrase inhibitors, α2- and...
    Angle Closure Glaucoma: Treatment01:28

    Angle Closure Glaucoma: Treatment

    Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
    Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

    Oral Hypoglycemic Agents: Biguanides and Glitazones

    Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
    Oral Hypoglycemic Agents: Glinides01:06

    Oral Hypoglycemic Agents: Glinides

    Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
    Hypoglycemia and Glucagon01:15

    Hypoglycemia and Glucagon

    Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
    Hypoglycemia01:26

    Hypoglycemia

    Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...